These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32524923)

  • 61. CHARACTERISTICS OF MANAGED ENTRY AGREEMENTS IN AUSTRALIA.
    Robinson MF; Mihalopoulos C; Merlin T; Roughead E
    Int J Technol Assess Health Care; 2018 Jan; 34(1):46-55. PubMed ID: 29277174
    [TBL] [Abstract][Full Text] [Related]  

  • 62. What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
    Carroll C; Houten R; Boland A; Kaltenthaler E; Dickson R
    Value Health; 2018 Mar; 21(3):341-350. PubMed ID: 29566842
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Botulinum toxin type A in the management of equinus in children with cerebral palsy: an evidence-based economic evaluation.
    Houltram J; Noble I; Boyd RN; Corry I; Flett P; Graham HK
    Eur J Neurol; 2001 Nov; 8 Suppl 5():194-202. PubMed ID: 11851748
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria.
    Lim SS; Vos T; Peeters A; Liew D; McNeil JJ
    Med J Aust; 2001 Nov; 175(9):459-64. PubMed ID: 11758073
    [TBL] [Abstract][Full Text] [Related]  

  • 65. What Can We Expect from Value-Based Funding of Medicines? A Retrospective Study.
    Harris A; Li JJ; Yong K
    Pharmacoeconomics; 2016 Apr; 34(4):393-402. PubMed ID: 26610347
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The Pharmacoeconomic Evaluation Process in Ireland.
    McCullagh L; Barry M
    Pharmacoeconomics; 2016 Dec; 34(12):1267-1276. PubMed ID: 27473640
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Drug policy down under: Australia's pharmaceutical benefits scheme.
    Duckett SJ
    Health Care Financ Rev; 2004; 25(3):55-67. PubMed ID: 15229996
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Which factors enhance positive drug reimbursement recommendation in Scotland? A retrospective analysis 2006-2013.
    Charokopou M; Majer IM; Raad Jd; Broekhuizen S; Postma M; Heeg B
    Value Health; 2015 Mar; 18(2):284-91. PubMed ID: 25773564
    [TBL] [Abstract][Full Text] [Related]  

  • 69. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Financial costs associated with monopolies on biologic medicines in Australia.
    Gleeson D; Townsend B; Lopert R; Lexchin J; Moir H
    Aust Health Rev; 2019 Feb; 43(1):36-42. PubMed ID: 29116927
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Home birth and the National Australian Maternity Services Review: too hot to handle?
    Dahlen H; Schmied V; Tracy SK; Jackson M; Cummings J; Priddis H
    Women Birth; 2011 Dec; 24(4):148-55. PubMed ID: 21074508
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The Australian model of immunization advice and vaccine funding.
    Nolan TM
    Vaccine; 2010 Apr; 28 Suppl 1():A76-83. PubMed ID: 20413003
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Review of a decision by the Medical Services Advisory Committee based on health technology assessment of an emerging technology: the case for remotely assisted radical prostatectomy.
    O'Malley SP; Jordan E
    Int J Technol Assess Health Care; 2007; 23(2):286-91. PubMed ID: 17493316
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Rising cost of anticancer drugs in Australia.
    Karikios DJ; Schofield D; Salkeld G; Mann KP; Trotman J; Stockler MR
    Intern Med J; 2014 May; 44(5):458-63. PubMed ID: 24612257
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cost driver analysis of statin expenditure on Australia's Pharmaceutical Benefits Scheme.
    Thai LP; Moss JR; Godman B; Vitry AI
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):419-33. PubMed ID: 26707482
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Is the quality of evidence in health technology assessment deteriorating over time? A case study on cancer drugs in Australia.
    Gao Y; Laka M; Merlin T
    Int J Technol Assess Health Care; 2023 May; 39(1):e28. PubMed ID: 37198927
    [TBL] [Abstract][Full Text] [Related]  

  • 79. "Drugs to avoid" to improve quality use of medicines: how is Australia faring?
    Vitry A; Mintzes B
    J Pharm Policy Pract; 2021 Jul; 14(1):60. PubMed ID: 34256874
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
    Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.